BR112013030894A2 - immune system modulators - Google Patents

immune system modulators

Info

Publication number
BR112013030894A2
BR112013030894A2 BR112013030894A BR112013030894A BR112013030894A2 BR 112013030894 A2 BR112013030894 A2 BR 112013030894A2 BR 112013030894 A BR112013030894 A BR 112013030894A BR 112013030894 A BR112013030894 A BR 112013030894A BR 112013030894 A2 BR112013030894 A2 BR 112013030894A2
Authority
BR
Brazil
Prior art keywords
immune system
same
system modulators
treating
symbols
Prior art date
Application number
BR112013030894A
Other languages
Portuguese (pt)
Inventor
Charles M Zepp
Grayson B Lipford
Original Assignee
Janus Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Biotherapeutics Inc filed Critical Janus Biotherapeutics Inc
Publication of BR112013030894A2 publication Critical patent/BR112013030894A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)

Abstract

novel immune system modulators 06.12.2012 a01n 43/90 wait... the present invention relates to a compound of formula i: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same. tradução do resumo resumo patente de invenção: "moduladores do sistema imune". a presente invenção refere-se a um composto de fórmula i: ou um sal farmaceuticamente aceitável do mesmo, em que os símbolos são como definidos no relatório descritivo; uma composição farmacêutica compreendendo o mesmo; e um método para tratar ou prevenir doenças de autoimunidade usando o mesmo. 19896317v1novel immune system modulators 06.12.2012 a01n 43/90 wait ... the present invention relates to a compound of formula i: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same. abstract of patent summary: "immune system modulators". The present invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmune diseases using the same. 19896317v1

BR112013030894A 2011-06-01 2012-06-01 immune system modulators BR112013030894A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161491965P 2011-06-01 2011-06-01
PCT/US2012/040417 WO2012167046A1 (en) 2011-06-01 2012-06-01 Novel immune system modulators

Publications (1)

Publication Number Publication Date
BR112013030894A2 true BR112013030894A2 (en) 2016-08-16

Family

ID=47259888

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030894A BR112013030894A2 (en) 2011-06-01 2012-06-01 immune system modulators

Country Status (11)

Country Link
US (4) US9359361B2 (en)
EP (1) EP2713736B1 (en)
JP (1) JP6093759B2 (en)
KR (1) KR102052215B1 (en)
CN (2) CN109912602A (en)
AU (1) AU2012262014B2 (en)
BR (1) BR112013030894A2 (en)
CA (1) CA2837227C (en)
IL (1) IL229541B (en)
RU (1) RU2606114C2 (en)
WO (1) WO2012167046A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2713736B1 (en) 2011-06-01 2023-08-02 Janus Biotherapeutics, Inc. Novel immune system modulators
US9260719B2 (en) * 2013-01-08 2016-02-16 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
JP2016540013A (en) * 2013-12-13 2016-12-22 武田薬品工業株式会社 Pyrrolo [3,2-C] pyridine derivatives as TLR inhibitors
DK3131902T3 (en) * 2014-04-14 2019-09-02 Boehringer Ingelheim Int Compounds like ROR-gamma modulators
WO2016029077A1 (en) * 2014-08-22 2016-02-25 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
JP6778259B2 (en) * 2015-10-01 2020-10-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pteridine derivative as a modulator of ROR gamma
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CN109715617B (en) 2016-07-30 2022-04-19 百时美施贵宝公司 Dimethoxyphenyl-substituted indole compounds as inhibitors of TLR7, TLR8 or TLR9
US10660877B2 (en) 2016-09-09 2020-05-26 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
US11370794B2 (en) 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
CN108069960A (en) * 2016-11-15 2018-05-25 江苏豪森药业集团有限公司 The preparation method of the western croak intermediate of Leo
ES2965044T3 (en) * 2017-07-18 2024-04-10 Merck Patent Gmbh TLR7/8 antagonists and their uses
WO2019028302A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of tlr7/8/9
JP7266576B2 (en) 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー [1,2,4]triazolo[4,3-a]pyridinyl-substituted indole compounds
JP7265554B2 (en) 2017-11-14 2023-04-26 ブリストル－マイヤーズ スクイブ カンパニー substituted indole compounds
DK3728252T3 (en) 2017-12-18 2023-11-13 Bristol Myers Squibb Co 4-AZAINDOLE COMPOUNDS
KR20200101956A (en) 2017-12-19 2020-08-28 브리스톨-마이어스 스큅 컴퍼니 6-azaindole compound
EA202091483A1 (en) 2017-12-19 2020-10-28 Бристол-Маерс Сквибб Компани AMIDE-SUBSTITUTED INDOLIC COMPOUNDS SUITABLE AS TLR INHIBITORS
EP3728225B1 (en) 2017-12-19 2022-11-09 Bristol-Myers Squibb Company Substituted indole compounds useful as tlr inhibitors
AU2018390610A1 (en) 2017-12-20 2020-08-06 Bristol-Myers Squibb Company Amino indole compounds useful as TLR inhibitors
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
CA3085942A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
CN114276351B (en) * 2020-09-27 2023-06-16 江苏恒瑞医药股份有限公司 Nitrogen-containing heterocyclic derivative, preparation method and medical application thereof
IL307203A (en) 2021-04-16 2023-11-01 Gilead Sciences Inc Thienopyrrole compounds

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US951655A (en) 1909-04-30 1910-03-08 Mergenthaler Linotype Gmbh Line-casting machine.
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2963478A (en) 1959-05-04 1960-12-06 Smith Kline French Lab 4, 7-diamino-nu-aralkyl-2-aryl-6-pteridinecarboxamides
US2975180A (en) * 1959-05-12 1961-03-14 Thomas S Osdene 4, 7-diamino-2-aryl-6-pteridinecarboxamides
US2963479A (en) * 1959-08-06 1960-12-06 Edward C Taylor 2-aryl-4, 7-diamino-6-cyanopteridines
US2963481A (en) * 1959-11-27 1960-12-06 Smith Kline French Lab 6-pteridinecarboxylic acid esters
US2998420A (en) * 1961-03-28 1961-08-29 Smith Kline French Lab 6-sulfamoylpteridine derivatives
US3028387A (en) 1961-04-21 1962-04-03 Smith Kline French Lab Dialkylaminoalkylaminopteridine derivatives
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AR006928A1 (en) 1996-05-01 1999-09-29 Pioneer Hi Bred Int AN ISOLATED DNA MOLECULA CODING A GREEN FLUORESCENT PROTEIN AS A TRACEABLE MARKER FOR TRANSFORMATION OF PLANTS, A METHOD FOR THE PRODUCTION OF TRANSGENIC PLANTS, A VECTOR OF EXPRESSION, A TRANSGENIC PLANT AND CELLS OF SUCH PLANTS.
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
JP5087758B2 (en) 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート Use of nucleic acids containing unmethylated CpG dinucleotides as adjuvants
ATE458053T1 (en) 1997-05-07 2010-03-15 Schering Corp HUMAN TOLL-LIKE RECEPTOR PROTEINS, ASSOCIATED REAGENTS AND METHODS
DE69838294T2 (en) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Process for the preparation of nucleic acid constructs
ATE356630T1 (en) 1998-04-03 2007-04-15 Univ Iowa Res Found METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM USING IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINE
CA2328602A1 (en) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
WO2005021003A2 (en) * 2003-08-29 2005-03-10 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
AU770551B2 (en) * 1998-12-28 2004-02-26 4-Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
GB2413324A (en) * 2004-04-22 2005-10-26 4 Aza Bioscience Nv Pharmaceutically active pteridine derivatives
CN1229142C (en) * 1999-08-12 2005-11-30 惠氏控股有限公司 NSAID and EFGR kinase inhibitor contg. compsn. for treatment or inhibition of colonic polyps and colorectal cancer
MXPA02003059A (en) 1999-09-27 2002-09-30 Univ Iowa Res Found Methods related to immunostimulatory nucleic acid induced interferon.
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
EP1283849A2 (en) 2000-05-25 2003-02-19 Schering Corporation Human receptor proteins; related reagents and methods
DE60229422D1 (en) 2001-08-17 2008-11-27 Coley Pharm Gmbh COMBINATION MOTIF IMMUNOSTIMULATING OLIGONUCLEOTIDES WITH IMPROVED EFFECT
JP2005516005A (en) * 2001-12-07 2005-06-02 バーテクス ファーマスーティカルズ インコーポレイテッド Pyrimidine-based compounds useful as GSK-3 inhibitors
EP2039683B1 (en) 2002-10-03 2012-12-19 Targegen, Inc. Vasculostatic agents and methods of use thereof
BR0315053A (en) * 2002-10-03 2005-08-09 Targegen Inc Vasculostatic agents, composition, article and preparation process
US20070032477A1 (en) 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
CN101104617B (en) * 2006-07-10 2010-06-23 北京摩力克科技有限公司 Dihydropyrimidine compounds and use of the same in preparing medicament for curing and preventing virosis
WO2008009079A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2009022185A2 (en) 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
EP2713736B1 (en) * 2011-06-01 2023-08-02 Janus Biotherapeutics, Inc. Novel immune system modulators
DE102011106709A1 (en) 2011-07-06 2013-01-10 Automatik Plastics Machinery Gmbh Method and device for producing granules

Also Published As

Publication number Publication date
JP2014518892A (en) 2014-08-07
RU2606114C2 (en) 2017-01-10
IL229541B (en) 2018-03-29
KR102052215B1 (en) 2019-12-04
CN103717070A (en) 2014-04-09
US9637489B2 (en) 2017-05-02
JP6093759B2 (en) 2017-03-08
WO2012167046A1 (en) 2012-12-06
EP2713736B1 (en) 2023-08-02
CA2837227A1 (en) 2012-12-06
EP2713736A4 (en) 2014-12-03
US9126996B2 (en) 2015-09-08
RU2013158933A (en) 2015-07-20
US20140079724A1 (en) 2014-03-20
US20160074403A1 (en) 2016-03-17
US20140221646A1 (en) 2014-08-07
CA2837227C (en) 2022-05-10
EP2713736A1 (en) 2014-04-09
AU2012262014A1 (en) 2014-01-23
US10117875B2 (en) 2018-11-06
IL229541A0 (en) 2014-01-30
US20170224699A1 (en) 2017-08-10
KR20140068814A (en) 2014-06-09
US9359361B2 (en) 2016-06-07
AU2012262014B2 (en) 2016-07-14
CN109912602A (en) 2019-06-21

Similar Documents

Publication Publication Date Title
BR112013030894A2 (en) immune system modulators
EA201490396A1 (en) ANTI-FLY VIRUS REPLICATION INHIBITORS
BR112014006271A2 (en) pharmaceutical compositions
BR112014003225A2 (en) vehicle-linked treprostinil prodrugs
BR112015031903A2 (en) compound, pharmaceutically acceptable salt of the compound, pharmaceutical composition and use of a compound
BR112015000150A2 (en) controlled release abuse deterrent pharmaceutical compositions
BR112014018879A8 (en) COMPOUND AND PHARMACEUTICAL COMPOSITION AND COMBINATION INCLUDING SAID COMPOUND
BR112015014458A2 (en) mannose derivatives for the treatment of bacterial infections
BR112013027670A2 (en) "Amide compound, pharmaceutical composition and medicament comprising it and rory antagonist"
BR112014026703A2 (en) dna-pk inhibitors
BR112013029692A2 (en) imidazole derivatives useful for treating arthritis
BR112014003079A2 (en) 1,2,3,4-tetrahydroquinoline derivative useful for treating diabetes
BR112015010791A2 (en) dihydropyrazole gpr40 modulators
BR112015010396A2 (en) combination therapy
BR112014010420A2 (en) pak inhibitors for the treatment of cell proliferative disorders
BR112015002118A2 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta [a] naphthalenes
BR112014015845A8 (en) azetidine derivatives, pharmaceutical compositions and their use
BR112015010779A2 (en) dihydropyrazole gpr40 modulators
MX2014004814A (en) Compounds and methods for enhancing innate immune responses.
BR112014010401A8 (en) HEPATITIS C VIRUS ROD-LIKE INHIBITORS CONTAINING THE FRAGMENT {2-[4-(BIPHENYL-4-IL)-1H-IMIDAZO-2-IL] PYRROLIDINE-1-CARBONYLMETHYL}AMINE
BR112014012459A2 (en) 2h-indazoles as ep2 receptor antagonists
BR112012033738A2 (en) Method for treating bipolar disorder
BR112014023423A2 (en) combination therapy
BR112015023669A2 (en) novel cyclosporine derivatives and their uses
BR112015019919A2 (en) bicyclic compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/90 , A61K 31/519 , C07D 239/00

Ipc: C07D 239/00 (2006.01), A61K 31/519 (2006.01), C07D

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]